Illumina, Inc. (NASDAQ:ILMN) Director Jay T. Flatley sold 3,300 shares of the company’s stock in a transaction dated Wednesday, October 10th. The stock was sold at an average price of $321.58, for a total value of $1,061,214.00. Following the sale, the director now owns 385,604 shares of the company’s stock, valued at approximately $124,002,534.32. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Shares of NASDAQ ILMN traded up $14.24 during trading hours on Friday, hitting $321.69. 1,856,939 shares of the company’s stock were exchanged, compared to its average volume of 891,778. Illumina, Inc. has a 1-year low of $198.21 and a 1-year high of $372.61. The company has a debt-to-equity ratio of 0.22, a quick ratio of 2.44 and a current ratio of 2.74. The stock has a market capitalization of $53.96 billion, a PE ratio of 80.42, a P/E/G ratio of 3.04 and a beta of 0.97.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Monday, July 30th. The life sciences company reported $1.43 earnings per share for the quarter, topping the consensus estimate of $1.11 by $0.32. Illumina had a return on equity of 26.64% and a net margin of 20.88%. The business had revenue of $830.00 million during the quarter, compared to analysts’ expectations of $786.88 million. During the same quarter in the previous year, the firm earned $0.82 EPS. The firm’s revenue was up 25.4% compared to the same quarter last year. As a group, equities research analysts forecast that Illumina, Inc. will post 5.46 EPS for the current fiscal year.
Several analysts have recently issued reports on ILMN shares. Citigroup upped their price target on Illumina from $275.00 to $330.00 and gave the stock a “buy” rating in a research note on Monday, June 25th. Cowen upped their price target on Illumina from $275.00 to $315.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 10th. Morgan Stanley boosted their price objective on Illumina from $195.00 to $210.00 and gave the stock an “underweight” rating in a research report on Friday, July 13th. Piper Jaffray Companies boosted their price objective on Illumina from $272.00 to $329.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 17th. Finally, Canaccord Genuity reissued a “buy” rating and set a $340.00 price objective (up previously from $330.00) on shares of Illumina in a research report on Friday, July 27th. Five equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $324.76.
A number of institutional investors have recently bought and sold shares of ILMN. Financial Gravity Wealth Inc. acquired a new position in Illumina in the 1st quarter valued at approximately $193,000. Nuveen Asset Management LLC raised its holdings in Illumina by 6.2% in the 1st quarter. Nuveen Asset Management LLC now owns 46,016 shares of the life sciences company’s stock valued at $10,879,000 after acquiring an additional 2,667 shares in the last quarter. United Capital Financial Advisers LLC raised its holdings in Illumina by 6.4% in the 1st quarter. United Capital Financial Advisers LLC now owns 38,082 shares of the life sciences company’s stock valued at $9,003,000 after acquiring an additional 2,304 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. raised its holdings in Illumina by 21.9% in the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 16,154 shares of the life sciences company’s stock valued at $3,817,000 after acquiring an additional 2,903 shares in the last quarter. Finally, LPL Financial LLC raised its holdings in Illumina by 38.6% in the 1st quarter. LPL Financial LLC now owns 9,228 shares of the life sciences company’s stock valued at $2,182,000 after acquiring an additional 2,568 shares in the last quarter. 89.84% of the stock is owned by hedge funds and other institutional investors.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
See Also: Stock Split
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.